» Articles » PMID: 35120347

Neurotrophic Keratopathy After Herpes Zoster Ophthalmicus

Overview
Journal Cornea
Specialty Ophthalmology
Date 2022 Feb 4
PMID 35120347
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The aim of this study was to describe risk factors for neurotrophic keratopathy (NK) after herpes zoster ophthalmicus (HZO).

Methods: This study was a retrospective review of all patients seen at the Auckland District Health Board with HZO from 2006 through 2016. Cox proportional hazards analysis was performed to examine time to development of neurotrophic keratitis.

Results: Eight hundred sixty-nine patients were included in the study with a median follow-up of 6.3 years (5504.4 patient-years). The median age was 65.5 years (interquartile range 52.9-75.4), and 456 subjects (52.5%) were male. NK developed in 58 patients (6.7%), with the highest hazard 1 to 2 years after onset of HZO. On univariate analysis, age, White ethnicity, best-corrected visual acuity (BCVA) at presentation, intraocular pressure, corneal involvement, uveitis, and number of recurrences were associated with increased risk of NK. On multivariate analysis, the following factors were significant: age (hazard ratio [HR] = 1.03; P = 0.021), White ethnicity (HR = 3.18; P = 0.015), BCVA (HR = 1.81; P = 0.026), uveitis (HR = 3.77; P = 0.001), and recurrence (HR = 1.34; P < 0.001). Vision loss (BCVA ≤6/15) was more frequent in subjects with NK (65.5% vs. 16.3%, P < 0.001).

Conclusions: NK is a relatively common and serious complication of HZO and occurs more frequently in older White individuals, those with poor visual acuity at presentation, and those with uveitis. Vision loss occurs in approximately two-thirds of patients.

Citing Articles

Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial.

Cohen E, Troxel A, Liu M, Hochman J, Baratz K, Mian S JAMA Ophthalmol. 2025; .

PMID: 40048183 PMC: 11886868. DOI: 10.1001/jamaophthalmol.2024.6114.


Corneal reinnervation in patients with severe neurotrophic keratopathy secondary to herpes zoster ophthalmicus after treatment with autologous serum tear drops.

Abazari A, Abbouda A, Cruzat A, Cavalcanti B, Pavan-Langston D, Hamrah P Cornea Open. 2024; 3(1).

PMID: 39145285 PMC: 11323069. DOI: 10.1097/coa.0000000000000029.


Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.

Litt J, Cunningham A, Arnalich-Montiel F, Parikh R Infect Dis Ther. 2024; 13(7):1439-1459.

PMID: 38834857 PMC: 11219696. DOI: 10.1007/s40121-024-00990-7.


Corneal nerve changes in herpes zoster ophthalmicus: a prospective longitudinal in vivo confocal microscopy study.

Mok E, Kam K, Young A Eye (Lond). 2023; 37(14):3033-3040.

PMID: 36906697 PMC: 10008015. DOI: 10.1038/s41433-023-02469-0.


Magic Bullets: The Coming Age of Meaningful Pharmacological Control of the Corneal Responses to Injury and Disease.

Wilson S J Ocul Pharmacol Ther. 2022; .

PMID: 36161879 PMC: 9700362. DOI: 10.1089/jop.2022.0088.